A restrospective observational cohort study comparing the risk of malignancy between patients treated with Vedolizumab versus Tumor Necrosis Factor-α (TNFα) antagonists in patients with Inflammatory Bowel Diseases
Latest Information Update: 14 Jun 2021
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab; Certolizumab pegol; Golimumab; Infliximab
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- 14 Jun 2021 New trial record
- 03 Jun 2021 Results published in the Digestive Diseases and Sciences